ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.
H.C. Wainwright 26th Annual Global Investment Conference
Presentation Time | Tuesday, September 10 at 5:00 PM ET |
Presenters | Sean Fu, PhD, Interim Chief Executive Officer (CEO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) |
Webcast link | |
Meetings | One-on-one and small group meetings: September 9 – 10, 2024 |
Management | Sean Fu, PhD, Interim CEO Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, CMO Tyler Ehler, Senior Director, Investor Relations |
The webcast will also be available under "Event Calendar" on I-Mab's IR website at https://ir.i-mabbiopharma.com/
For more information, please contact your H.C. Wainwright representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.72 |
| Daily Change: | -0.84 -12.80 |
| Daily Volume: | 4,097,947 |
| Market Cap: | US$659.340M |
October 14, 2025 September 08, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
